Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.81 USD
Change Today -0.09 / -0.16%
Volume 549.9K
CPHD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Open
$56.64
Previous Close
$56.90
Day High
$56.92
Day Low
$54.65
52 Week High
03/19/15 - $60.00
52 Week Low
07/31/14 - $36.94
Market Cap
4.1B
Average Volume 10 Days
463.5K
EPS TTM
$-0.43
Shares Outstanding
71.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert Infinity System for high volume testing. The company sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; Life Technologies Corporation to develop reagents for use in the USPS BDS program; AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, and others to develop Xpert Carba-R, a rapid diagnostic test; and Paul G. Allen Family Foundation and the BMGF to develop Xpert Ebola, a rapid test that. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,400 Employees
Last Reported Date: 02/26/15
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $664.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $398.0K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Executive Vice President of Worldwide Commerc...
Total Annual Compensation: $236.2K
Compensation as of Fiscal Year 2014.

cepheid inc (CPHD) Key Developments

Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test

Cepheid announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration (FDA) for Xpert® Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert® Systems. Ebola was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The 2014 Ebola epidemic is the large in history, affecting multiple countries in West Africa. In the United States four cases have been reported: two imported cases that included one death, and two locally acquired cases in healthcare workers.

Cepheid Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 10:25 AM

Cepheid Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 10:25 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States.

Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test

Cepheid announced it has received clearance from the U.S. Food & Drug Administration (FDA) for expanded claims on its Xpert® MTB/RIF test. Xpert MTB/RIF detects Mycobacterium tuberculosis complex (MTB-complex) DNA and in positive specimens, provides simultaneous identification of rifampin-resistance associated mutations of the rpoB gene. The expanded product claim enables clinicians to use either one or two negative Xpert MTB/RIF test results, in conjunction with other clinical and laboratory data, to remove patients from airborne infection isolation (AII), commonly referred to as respiratory isolation. The test runs on the Cepheid GeneXpert® System, the molecular diagnostic platform with over 8,000 systems deployed globally in both developed and emerging market countries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $56.81 USD -0.09

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DiaSorin SpA €41.02 EUR +0.09
Luminex Corp $16.06 USD +0.06
Meridian Bioscience Inc $18.88 USD -0.20
QIAGEN NV €23.26 EUR -0.284
Sequenom Inc $3.93 USD -0.02
View Industry Companies
 

Industry Analysis

CPHD

Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.3x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit www.cepheid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.